Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35010 | 0.84 | HSD17B1 (0.48) | KCNK3KCNK9ALDH1A1PTGS1 | |
| SCHEMBL3507106 | 0.84 | MAPT (0.50) | MAPTGAAKCNK3KCNK9LMNA | |
| SCHEMBL3717986 | 0.84 | GAA (0.56) | MAPTGAANR1H2NR1H3KCNK3 | |
| SCHEMBL31369140 | 0.84 | GAA (0.56) | MAPTGAANR1H2NR1H3KCNK3 | |
| SCHEMBL15608407 | 0.83 | POLB (0.54) | MAPTKCNK3KCNK9HSD17B10MEN1 | |
| SCHEMBL158167 | 0.82 | G6PD (0.55) | MAPTGAAKCNK3KCNK9LMNA | |
| SCHEMBL1125117 | 0.81 | KAT6A (0.52) | MAPTGAANR1H2NR1H3KCNK3 | |
| SCHEMBL2910045 | 0.81 | NR1H2 (0.50) | MAPTGAANR1H2NR1H3KCNK3 | |
| SCHEMBL29941229 | 0.81 | KAT6A (0.52) | MAPTGAANR1H2NR1H3KCNK3 | |
| Hydrochloric Acid SCHEMBL11631331 | 0.81 | G6PD (0.53) | MAPTGAAKCNK3KCNK9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2897947-B1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242941-B2 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-METERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2014047374-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| CN-100418955-C | Novel Benzo-fused heterocycles | ACTELION PHARMOUEUTICALS LTD (CH) | 2008-09-17 | — | — | CN | disclosed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| CN-1914173-A | Quinolines useful in treating cardiovascular disease | WYETH CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1538848-A | Novel Benzo-fused heterocycles | ������˹ҩƷ��˾ | 2004-10-20 | — | — | CN | disclosed |
| US-3941803-A | 2-(Imidazol-1-yl)benzophenones | THE UPJOHN COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | MAPT 4016/4885GAA 2674/4885NR1H2 2/4885 |
| US-20150239851-A1 | ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | MAPT 4661/4885GAA 4151/4885NR1H2 9/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | MAPT 4520/4885GAA 1501/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.